Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis

Abstract

Transdermal nicotine administered at the highest tolerated dosage (< or = 22 mg/d) for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active ulcerative colitis.